Running the Big Numbers, page-8

Hi Stone - your post prompted me to revisit some previous valuations from analyst's reports and boy are there some wide variations in the numbers. Ballieu Holst report of 13/6/14 has a base valuation of $423m and an optimistic valuation of $945m which include a substantial value on the technology but doesn't include infusions or any of the later adapt products. Patersons report of 7/3/17 comes up with a figure of $126m which doesn't include some of the latest developments nor any value for the technology. As one of our football commentators says - "it's a bigger mystery than the original price of a persian rug".
It would be helpful if the Company could get an updated report from one of the analysts.